New hope for brain cancer: CAR-T plus stem cell combo targets hard-to-treat lymphoma
NCT ID NCT07198464
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 25 times
Summary
This study tests a new treatment for primary central nervous system lymphoma (PCNSL), a rare brain cancer. It combines CAR-T cell therapy, a stem cell transplant, and two targeted drugs (orelabrutinib and sintilimab) to see if it can control the disease better. The study will include 30 adults aged 18-60 who have not had CAR-T or stem cell transplant before. The main goals are to measure how long patients live without the cancer getting worse and how many patients respond to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.